CN106661030B - 用于药物制剂中的PI3K δ选择性抑制剂的改良形式 - Google Patents

用于药物制剂中的PI3K δ选择性抑制剂的改良形式 Download PDF

Info

Publication number
CN106661030B
CN106661030B CN201580034288.7A CN201580034288A CN106661030B CN 106661030 B CN106661030 B CN 106661030B CN 201580034288 A CN201580034288 A CN 201580034288A CN 106661030 B CN106661030 B CN 106661030B
Authority
CN
China
Prior art keywords
salt
disease
tgr
ptsa salt
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580034288.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106661030A (zh
Inventor
斯瓦鲁普·库马尔·文卡塔·萨蒂亚·瓦卡拉恩卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhizen Pharmaceuticals AG
Original Assignee
Rhizen Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals AG filed Critical Rhizen Pharmaceuticals AG
Priority to CN202010471226.5A priority Critical patent/CN111635406A/zh
Publication of CN106661030A publication Critical patent/CN106661030A/zh
Application granted granted Critical
Publication of CN106661030B publication Critical patent/CN106661030B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580034288.7A 2014-05-27 2015-05-26 用于药物制剂中的PI3K δ选择性抑制剂的改良形式 Expired - Fee Related CN106661030B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010471226.5A CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2597CH2014 2014-05-27
IN2597/CHE/2014 2014-05-27
IN2596/CHE/2014 2014-05-27
IN2596CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010471226.5A Division CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Publications (2)

Publication Number Publication Date
CN106661030A CN106661030A (zh) 2017-05-10
CN106661030B true CN106661030B (zh) 2020-06-30

Family

ID=53499042

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580034288.7A Expired - Fee Related CN106661030B (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3K δ选择性抑制剂的改良形式
CN202010471226.5A Pending CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010471226.5A Pending CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Country Status (22)

Country Link
US (4) US9969740B2 (https=)
EP (2) EP3971188A1 (https=)
JP (3) JP6987501B2 (https=)
KR (1) KR20170007480A (https=)
CN (2) CN106661030B (https=)
AU (1) AU2015265542B2 (https=)
BR (1) BR112016027674A2 (https=)
CA (1) CA2949932C (https=)
CY (1) CY1124316T1 (https=)
DK (1) DK3149000T3 (https=)
EA (1) EA032506B1 (https=)
ES (1) ES2880999T3 (https=)
HR (1) HRP20211151T1 (https=)
HU (1) HUE054916T2 (https=)
IL (1) IL249058B2 (https=)
LT (1) LT3149000T (https=)
PL (1) PL3149000T3 (https=)
PT (1) PT3149000T (https=)
RS (1) RS62136B1 (https=)
SI (1) SI3149000T1 (https=)
SM (1) SMT202100532T1 (https=)
WO (1) WO2015181728A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880999T3 (es) * 2014-05-27 2021-11-26 Rhizen Pharmaceuticals S A Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
CN110191720A (zh) 2016-09-09 2019-08-30 Tg治疗有限公司 用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合
JP2022540466A (ja) 2019-07-15 2022-09-15 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 非晶質ウムブラリシブモノトシレート
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440408A (zh) * 2000-04-25 2003-09-03 艾科斯有限公司 人磷脂酰肌醇3－激酶δ的抑制剂
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CN102458410A (zh) 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
ES2880999T3 (es) * 2014-05-27 2021-11-26 Rhizen Pharmaceuticals S A Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440408A (zh) * 2000-04-25 2003-09-03 艾科斯有限公司 人磷脂酰肌醇3－激酶δ的抑制剂
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Also Published As

Publication number Publication date
JP2017516785A (ja) 2017-06-22
IL249058B2 (en) 2023-03-01
JP6987501B2 (ja) 2022-01-05
JP2020122022A (ja) 2020-08-13
CN111635406A (zh) 2020-09-08
US10414773B2 (en) 2019-09-17
ES2880999T3 (es) 2021-11-26
EP3149000A1 (en) 2017-04-05
IL249058B (en) 2022-11-01
PT3149000T (pt) 2021-07-27
EA201692255A1 (ru) 2017-04-28
RS62136B1 (sr) 2021-08-31
SMT202100532T1 (it) 2021-11-12
US9969740B2 (en) 2018-05-15
HUE054916T2 (hu) 2021-10-28
LT3149000T (lt) 2021-09-10
CY1124316T1 (el) 2022-07-22
DK3149000T3 (da) 2021-08-30
BR112016027674A2 (pt) 2017-08-15
EP3149000B1 (en) 2021-06-30
US10947244B2 (en) 2021-03-16
US20190016725A1 (en) 2019-01-17
US20210269446A1 (en) 2021-09-02
CA2949932A1 (en) 2015-12-03
WO2015181728A1 (en) 2015-12-03
US20170121336A1 (en) 2017-05-04
CN106661030A (zh) 2017-05-10
AU2015265542B2 (en) 2019-05-09
HRP20211151T1 (hr) 2021-10-15
US20190382411A1 (en) 2019-12-19
AU2015265542A1 (en) 2016-12-08
KR20170007480A (ko) 2017-01-18
JP2022082680A (ja) 2022-06-02
EP3971188A1 (en) 2022-03-23
IL249058A0 (en) 2017-01-31
EA032506B1 (ru) 2019-06-28
PL3149000T3 (pl) 2021-11-02
CA2949932C (en) 2021-08-10
SI3149000T1 (sl) 2021-09-30

Similar Documents

Publication Publication Date Title
CN106661030B (zh) 用于药物制剂中的PI3K δ选择性抑制剂的改良形式
JP7291839B2 (ja) 固体形態のｃｄｋ４阻害薬
CN110913861B (zh) G1t38的形态学形式及其制造方法
JP2020528884A (ja) キナーゼを調節する化合物の製剤
TW202131930A (zh) 抗癌核荷爾蒙受體標靶化合物
CN116615426A (zh) Fgfr抑制剂和其制造和使用方法
JP2025503139A (ja) 固形腫瘍の治療のためのユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤
TW202108570A (zh) 抗癌核荷爾蒙受體標靶化合物
TWI920088B (zh) Ｓｉｋ-３抑制劑及其用途
HK1236026B (en) Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
EA042667B1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
JP7850883B2 (ja) Ｇ１ｔ３８の形態及びその製造方法
HK40116672A (zh) 治疗实体瘤的泛素特异性处理蛋白酶1(usp1)抑制剂
HK40087859A (zh) Cdk4抑制剂的固体形式
BR112019027967B1 (pt) Forma b cristalina isolada, composição farmacêutica, uso de um composto ou composição, e, processo para produzir forma b cristalina

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200630

CF01 Termination of patent right due to non-payment of annual fee